Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235687 | 1.00 | PPARG (0.46) | PPARGPPARAPDK1PDK2PDK3 | |
| SCHEMBL29067591 | 0.86 | PPARG (0.46) | PPARGPPARAPDK1PDK2PDK3 | |
| SCHEMBL3934515 | 0.84 | ALDH1A1 (0.42) | PPARGPPARAPDK1PDK2PDK3 | |
| SCHEMBL27277369 | 0.84 | PPARG (0.59) | PPARGPPARA | |
| SCHEMBL3276911 | 0.84 | PDCD1 (0.48) | PPARGALDH1A1MAPTPKM | |
| SCHEMBL10861615 | 0.83 | PPARG (0.62) | PPARGPPARAALDH1A1 | |
| SCHEMBL679864 | 0.80 | RAB9A (0.47) | ALDH1A1LMNAMAPTPKMHTT | |
| SCHEMBL7561830 | 0.80 | RAB9A (0.47) | ALDH1A1LMNAMAPTPKMHTT | |
| SCHEMBL12984801 | 0.78 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTHTT | |
| SCHEMBL1767596 | 0.78 | AKR1C3 (0.46) | PDK1PDK2PDK3PDK4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231532-A1 | Supported Metal Catalysts | JOHNSON MATTHEY PLC (GB) | 2020-07-23 | — | — | US | disclosed |
| US-20180099923-A1 | Supported Metal Catalysts | JOHNSON MATTHEY PLC (GB) | 2018-04-12 | — | — | US | disclosed |
| CN-102834174-B | Supported metal catalysts | 约翰逊马西有限公司 | 2017-11-03 | — | — | CN | disclosed |
| EP-2536500-B1 | SUPPORTED METAL CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2016-12-07 | — | — | EP | disclosed |
| US-20130072722-A1 | SUPPORTED METAL CATALYSTS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2013-03-21 | — | — | US | disclosed |
| EP-2536500-A1 | SUPPORTED METAL CATALYSTS | Johnson Matthey PLC (GB) | 2012-12-26 | — | — | EP | disclosed |
| CN-102834174-A | Supported metal catalysts | JOHNSON MATTHEY PLC | 2012-12-19 | — | — | CN | disclosed |
| WO-2011101679-A1 | SUPPORTED METAL CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2011-08-25 | — | — | WO | disclosed |
| EP-1250353-B1 | P21 DERIVED PEPTIDES CAPABLE OF INHIBITING CDK/CYCLIN COMPLEXES | CYCLACEL LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-7449544-B2 | p21 peptides | CYCLACEL LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| US-20060293245-A1 | P21 derived peptides and uses thereof | CYCLACEL LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| US-20050153894-A1 | p21 peptides | CYCLACEL LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| US-20040176301-A1 | p21 peptides | CYCLACEL LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
| US-20030036628-A1 | p21 peptides | CYCLACEL LIMITED (GB) | 2003-02-20 | — | — | US | disclosed |
| EP-1250353-A2 | P21 DERIVED PEPTIDES CAPABLE OF INHIBITING CDK/CYCLIN COMPLEXES | Cyclacel Limited (GB) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001040142-A2 | P21 DERIVED PEPTIDES CAPABLE OF INHIBITING CDK/CYCLIN COMPLEXES | CYCLACEL LIMITED (GB) | 2001-06-07 | — | — | WO | disclosed |
| EP-0174375-A1 | PROCESS FOR PREPARING N-ACYLPHENYLALANINES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1986-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072722-A1 | SUPPORTED METAL CATALYSTS | SOD1, HNMT, SOD3 | PPARG 4398/4885PPARA 3524/4885PDK1 2242/4885 |
| US-20060293245-A1 | P21 derived peptides and uses thereof | CDK4, CDK2AP2, CDK2 | PPARG 1480/4885PPARA 1893/4885PDK1 225/4885 |
| US-20050153894-A1 | p21 peptides | CDK2, CDK4, CDKN1A | PPARG 1481/4885PPARA 2118/4885PDK1 292/4885 |
| US-20040176301-A1 | p21 peptides | CDK2, CDK4, CDKN1A | PPARG 1481/4885PPARA 2118/4885PDK1 292/4885 |
| US-20030036628-A1 | p21 peptides | CDK2, CDK4, CDKN1A | PPARG 1481/4885PPARA 2118/4885PDK1 292/4885 |
| US-20200231532-A1 | Supported Metal Catalysts | SOD1, HNMT, SOD3 | PPARG 4398/4885PPARA 3524/4885PDK1 2242/4885 |
| US-20180099923-A1 | Supported Metal Catalysts | SOD1, HNMT, SOD3 | PPARG 4398/4885PPARA 3524/4885PDK1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.